Carrizo Target Lowered After Asset Sale and 4 Must-See Stock Analyses
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR): Lazard Capital said that this weekend’s New York Times article on Questcor Pharmaceuticals, Inc. raised no new issues, but noted that the report slants in a negative direction. The firm believes that while the article increased the profile of the high price of Acthar, it added little to the debate surrounding shares of Questcor. Lazard Capital has a Buy rating on the stock with a $74 price target.
Carrizo Oil & Gas Inc. (NASDAQ:CRZO): Following the North Sea asset sale, Baird lowered their price target on Carrizo Oil & Gas Inc. The firm believes the sale is positive, as the results have a focused strategy, but it may take some time to play out. However, since the story is less compelling in the near-term, Baird lowered their price target but shares remain Outperform rated.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Pebblebrook Hotel Trust (NYSE:PEB): Following its better than expected refinancing, Baird continues to recommend Pebblebrook Hotel Trust. The firm believes the move will lower its risks and increase returns since they will have more cash on hand to fund acquisition opportunities. Shares are Outperform rated with a $25 price target.
Intel Corporation (NASDAQ:INTC): Wells Fargo believes that Intel Corporation could benefit from strong x86 server-related processor growth, driven by increased cloud computing and data traffic. The firm believes that the company could gain market share in mobile processors while maintaining current margin levels.
Omeros Corporation (NASDAQ:OMER): Maxim said that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm added that pain is directly related to inflammation and the surgical process itself. Maxim found that Omeros Corporation shares oversold and said they are a buyer of the stock.
Don’t Miss: This Free Service Is Costing Google.